About Eugia Pharma Specialities Limited
Data last updated:
Eugia Pharma Specialities Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 April 2013 and has been in existence for over 13 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24297TG2013PLC087048. Its GSTIN is 36AADCE3429K1ZK (Telangana). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹800 Cr and a paid-up capital of ₹621.01 Cr. It is led by directors including Madan Mohan Reddy Mettu and Veerayya Chowdary Kosaraju.
Its last annual general meeting (AGM) was held on 08 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No.2 Maitrivihar, Hyderabad, Telangana, India – 500038.
As per the financials filed for FY 2025, the company reported a revenue of ₹4,828.71 Cr, a growth of 12% compared to the previous year. For the same year it recorded a net profit of ₹931.86 Cr (net margin 19.3%) and EBITDA of ₹1,650.15 Cr (EBITDA margin 34.2%). Revenue has grown at a compounded annual rate (CAGR) of 31% over three years and 102% over five years.
The company has about 2,763 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
As per MCA filings, the company has satisfied charges of ₹724 Cr on record. Court records list 75 cases involving the company, including 74 filed by the company and 1 filed against it; 49 cases are pending. The company has 12 deals on record (6 rights issues, 5 secondary share transfers, 1 debt financing), with disclosed funding of ₹575 Cr; the latest was in March 2025. Its 9 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is MSN Laboratories Private Limited with revenue of ₹6,761.18 Cr. The company has 12 MSME Form 1 returns on record between 2019 and 2024, listing 545 overdue payments to 137 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eugiapharma.com.
Company details
CIN history
Eugia Pharma Specialities has one previous CIN (Corporate Identification Number): U24297AP2013PLC087048. The current CIN is U24297TG2013PLC087048, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24297TG2013PLC087048 | Current |
| U24297AP2013PLC087048 | Previous |
Contact details
Eugia Pharma Specialities Limited's registered office is in Hyderabad, Telangana. Its website is eugiapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No.2 Maitrivihar, Hyderabad, Telangana, India – 500038
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Eugia Pharma Specialities Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Eugia Pharma Specialities is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Eugia Pharma Specialities Limited, buy the company report.
Financials of Eugia Pharma Specialities Limited
FY 2025 filings availableEugia Pharma Specialities Limited reported revenue of ₹4,828.71 Cr (up 12% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 102% over five years, including 12% growth in the latest year. EBITDA rose 25% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1,650.15 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹931.86 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 34.2% | ||||
| Net Profit Margin | 19.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Eugia Pharma Specialities Limited, buy the company report.
Board of directors and KMP of Eugia Pharma Specialities Limited
Eugia Pharma Specialities Limited currently reports 5 directors and 1 key managerial person. 24 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Madan Mohan Reddy Mettu Also directs: MSS Packaging Industries LLP, Aurobindo Pharma Ltd, Engenra Biologics Private Limited and 5 more | Director | 17 Apr 2013 | 13 Years 6 Months | Current |
| Veerayya Chowdary Kosaraju Also directs: CCL Products (India) Limited, Reliance Industries Limited, Divi's Laboratories Limited and 5 more | Director | 01 Dec 2021 | 4 Years 11 Months | Current |
| Yugandhar Puvvala | Ceo | 01 Oct 2021 | 5 Years 1 Months | Current |
| Santhanam Subramanian Also directs: Engenra Biologics Private Limited, Theranym Biologics Private Limited, Eugia Steriles Private Limited and 5 more | Director | 01 Oct 2021 | 5 Years 1 Months | Current |
| Ragunathan Kannan Also directs: K Vijayaraghavan & Associates LLP, Premier Energies Limited, Transcon Ind Limited and 5 more | Director | 01 Dec 2021 | 4 Years 11 Months | Current |
| Sundari Raviprasad Pisupati | Director | 01 Dec 2021 | 4 Years 11 Months | Current |
Peer comparison
Eugia Pharma Specialities Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| MSN Laboratories Private Limited | ₹6,761.18 Cr (FY 2024) | 27.0% | Hyderabad, Telangana, India | |||
| Abbott India Limited | ₹6,684.73 Cr (FY 2025) | 10.0% | Mumbai, Maharashtra, India | |||
| Micro Labs Limited | ₹6,499.64 Cr (FY 2025) | -2.0% | Bengaluru, Karnataka, India | |||
| Aristo Pharmaceuticals Private Limited | ₹5,363.3 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Usv Private Limited | ₹5,202.13 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Eugia Pharma Specialities Limitedthis company | ₹4,828.71 Cr (FY 2025) | ₹931.86 Cr | 19.3% | 12.0% | 2,763 | Hyderabad, Telangana, India |
| Natco Pharma Limited | ₹4,784 Cr (FY 2025) | 16.0% | Hyderabad, Telangana, India | |||
| Ajanta Pharma Limited | ₹4,742.6 Cr (FY 2025) | 10.0% | Mumbai, Maharashtra, India | |||
| Strides Pharma Science Limited | ₹4,624.06 Cr (FY 2025) | 18.0% | Thane, Maharashtra, India | |||
| Apl Healthcare Limited | ₹4,412.92 Cr (FY 2025) | 39.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Eugia Pharma Specialities Limited, buy the company report.
Auditor
Eugia Pharma Specialities Limited is audited by Walker Chandiok & Co LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2024 | 001076N/N500013 |
Shareholding
The shareholding of Eugia Pharma Specialities Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Eugia Pharma Specialities Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Sep 2019 | 100295568 | Others | ₹105 Cr | Satisfied | |
| 06 Jul 2017 | 100114100 | Others | ₹500 Cr | Satisfied | |
| 24 Feb 2014 | 10481778 | Export Import Bank of India | ₹119 Cr | Satisfied |
To see the full charge records of Eugia Pharma Specialities Limited, buy the company report.
Total charge records: 3 View all charges
Deals & funding
Eugia Pharma Specialities Limited has 12 deals on record (6 rights issues, 5 secondary share transfers, 1 debt financing), with disclosed funding of ₹575 Cr; the latest was in March 2025.
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Secondary share transfer | Undisclosed | Buyer: Aurobindo Pharma Ltd Seller: Mviyes Pharma Ventures Private Limited |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: Aurobindo Pharma Ltd , Mviyes Pharma Ventures Private Limited Seller: Curepro Parenterals Limited |
| Nov 2020 | Debt financing | ₹575 Cr | Investors: Aurobindo Pharma Ltd |
| Apr 2020 | Rights issue | ₹143.91 Cr | Investors: Curepro Parenterals Limited , Mviyes Pharma Ventures Private Limited |
| Oct 2019 | Secondary share transfer | Undisclosed | Buyer: Mviyes Pharma Ventures Private Limited Seller: Celon Laboratories Private Limited |
To see the full deal history of Eugia Pharma Specialities Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Eugia Pharma Specialities Limited has 75 court cases on record: 74 filed by Eugia Pharma Specialities, 1 filed against it. 49 cases are pending and 26 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 54 | 1 | 31 |
| High courts | 21 | 0 | 18 |
Cases on record (5 of 75)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Court case (MVOP) | Filed against the company | Pending |
| District court, Hyderabad CCC, Telangana | Civil suit | Filed by the company against an individual | Pending |
| District court, Hyderabad CCC, Telangana | Civil suit | Filed by the company against an individual | Pending |
| District court, Hyderabad CCC, Telangana | Civil suit | Filed by the company against an individual | Pending |
| District court, Hyderabad CCC, Telangana | Civil suit | Filed by the company against an individual | Pending |
To see the full case history of Eugia Pharma Specialities Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Eugia Pharma Specialities Limited was last rated by Indiarating on 29 Jan 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Indiarating | 29 Jan 2021 |
To see the full credit ratings and regulatory alerts of Eugia Pharma Specialities Limited, buy the company report.
MSME payment delays
Eugia Pharma Specialities Limited has 12 MSME Form 1 returns on record between 2019 and 2024, listing 545 overdue payments to 137 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 137)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Enviro-Engineers | |||
| an individual supplier | |||
| CK Enterprises LLP | |||
| Sofac Technosys Private Limited |
To see the full MSME payment records of Eugia Pharma Specialities Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Eugia Pharma Specialities has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Eugia Steriles Private Limited | U24239TG2020PTC141428 | |
| Eugia Sez Private Limited | U24299TG2021PTC148856 |
To see the full group structure of Eugia Pharma Specialities Limited, buy the company report.
Employees & EPFO
Eugia Pharma Specialities Limited has a workforce of 2,763 employees on its EPFO records as of Feb 14, 2025, across 2 active EPFO establishments.
GST
Eugia Pharma Specialities has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AADCE3429K1ZK | Telangana | Active | 01 Jul 2017 |
| 36AADCE3429K2ZJ | Telangana | Active | 31 Aug 2021 |
| 08AADCE3429K1ZJ | Rajasthan | Active | 29 Dec 2020 |
To see the full GST registrations and return filing status of Eugia Pharma Specialities Limited, buy the company report.
Recent activity
Eugia Pharma Specialities Limited has 27 board changes on record since 2013: 6 appointments and 21 cessations. The latest: Ganadhish Kamat ceased to be Additional Director on 27 Dec 2021.
27 earlier events are in the company report.
Frequently asked questions
Eugia Pharma Specialities is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 April 2013 (13+ years old) and is registered under CIN U24297TG2013PLC087048.
Eugia Pharma Specialities has 6 current directors and KMP:
- Madan Mohan Reddy Mettu - Director
- Veerayya Chowdary Kosaraju - Director
- Santhanam Subramanian - Director
- Ragunathan Kannan - Director
- Sundari Raviprasad Pisupati - Director
- Yugandhar Puvvala - Ceo
The latest financial statements of Eugia Pharma Specialities on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 08 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Eugia Pharma Specialities is 36AADCE3429K1ZK, registered in Telangana. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 36AADCE3429K2ZJ (Telangana), 08AADCE3429K1ZJ (Rajasthan).
The CIN (Corporate Identification Number) of Eugia Pharma Specialities is U24297TG2013PLC087048. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Eugia Pharma Specialities has 75 court cases on record: 74 filed by the company and 1 filed against it. 49 are pending. Most are in the district courts.
Eugia Pharma Specialities was incorporated on 17 April 2013, making it 13+ years old. It is registered with the Registrar of Companies, Hyderabad.
Eugia Pharma Specialities has 12 deals on record (6 rights issues, 5 secondary share transfers, 1 debt financing), with disclosed funding of ₹575 Cr; the latest was in March 2025.
The peers of Eugia Pharma Specialities by revenue are MSN Laboratories Private Limited, Abbott India Limited, Micro Labs Limited, Aristo Pharmaceuticals Private Limited, Usv Private Limited and 4 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Ganadhish Kamat ceased to be Additional Director on 27 Dec 2021. Ragunathan Kannan ceased to be Additional Director on 27 Dec 2021. Santhanam Subramanian ceased to be Additional Director on 27 Dec 2021. Eugia Pharma Specialities has 27 board changes on record in total.
Eugia Pharma Specialities has 12 MSME Form 1 returns on record between 2019 and 2024, listing 545 overdue payments to 137 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Eugia Pharma Specialities can be reached through the website eugiapharma.com. Its registered office is in Hyderabad, Telangana, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
